Regeneron, AbbVie, Mohawk Price Targets, November 2 2026
Regeneron
Regeneron develops antibody drugs. It shares profits with Sanofi on Dupixent and sells the eye drug EYLEA HD and the cancer drug Libtayo. The company is based in Tarrytown, New York. It reported third-quarter results before the open on Friday. Revenue came to $5.12 billion, 12.8% above the $4.54 billion consensus. Adjusted earnings were $20.07 a share, 25% above the $16.06 expected.
What Drove Regeneron’s Quarter
Dupixent drove the beat. Its global sales grew 35% to $6.5 billion, and Regeneron’s collaboration revenue from Sanofi grew 68% to $2.72 billion.
Total revenue grew 36%. U.S. sales of EYLEA HD grew 62% to $699 million. Libtayo sales grew 51% to $550 million. Regeneron also raised its gross margin outlook for the year to about 86% on an adjusted basis.
Eleven Desks Raise Regeneron
John Newman of Canaccord kept Buy and raised his target from $922 to $1,175 today, a Monday. Tazeen Ahmad of BofA kept Buy and raised her target from $908 to $1,030. Carter Gould of Cantor Fitzgerald kept Overweight and raised his target from $795 to $980. Brian Abrahams of RBC Capital kept Sector Perform and raised his target from $810 to $913. Gregory Renza of Truist kept Buy and raised his target from $780 to $982.
Yatin Suneja of Guggenheim kept Buy and raised his target from $1,030 to $1,100. Mohit Bansal of Wells Fargo kept Equal Weight and raised his target from $750 to $925. Brian Skorney of Baird kept Neutral and raised his target from $761 to $875 on Friday.
Four more raised later in the day. Cory Kasimov of Evercore ISI kept Outperform and raised his target from $900 to $1,075. David Risinger of Leerink Partners kept Market Perform and raised his target from $835 to $997. Matthew Harrison of Morgan Stanley kept Equal Weight and raised his target from $779 to $855. Jeffrey Walch of Bernstein kept Market Perform and raised his target from $756 to $812.
Regeneron’s Record on AnaChart
Regeneron draws 26 covering analysts on AnaChart. Their average target is $842.29. Ratings split 65.88% Buy and 34.12% Hold. AnaChart’s tracking shows 84.33% of Regeneron targets get met, after about 225 days on average.
AbbVie
AbbVie sells immune disease drugs, including Skyrizi and Rinvoq, along with brain drugs such as Vraylar and the Botox franchise. The company is based in North Chicago, Illinois. It reported third-quarter results before the open on Friday. Revenue came to $17.4 billion, 0.2% above the $17.36 billion consensus. Adjusted earnings were $3.82 a share, 2.1% above the $3.74 expected.
What Drove AbbVie’s Quarter
Skyrizi and Rinvoq led the beat. Skyrizi sales grew 22.7% to $5.78 billion, and Rinvoq grew 23.9% to $2.71 billion. Humira sales shrank 31.2% to $683 million.
Total sales grew 10.3%. AbbVie raised its full-year adjusted earnings outlook to $13.95 to $13.99 a share, from $13.76 to $13.96. Chief executive Robert Michael said AbbVie was “once again increasing” its forecast.
Seven Desks Raise AbbVie
Gary Nachman of Canaccord kept Buy and raised his target from $290 to $338 today. Gould of Cantor Fitzgerald kept Overweight and raised his target from $290 to $325. Bansal of Wells Fargo kept Overweight and raised his target from $300 to $340. Vamil Divan of Guggenheim kept Buy and raised his target from $288 to $322. Michael Yee of UBS kept Neutral and raised his target from $275 to $295. Later the same day, Terence Flynn of Morgan Stanley kept Overweight and raised his target from $310 to $346. Trung Huynh of RBC Capital kept Outperform and raised his target from $280 to $330.
AbbVie’s Record on AnaChart
AbbVie draws 18 covering analysts on AnaChart. Their average target is $272.39. Ratings split 80.3% Buy and 19.7% Hold. AnaChart’s tracking shows 93.7% of AbbVie targets get met, after about 417 days on average. Divan has met all 45 of his targets on the stock, with an average potential upside of 4.17%. Gould has met all 32 of his, with an average potential upside of 6.45%.
Mohawk Industries
Mohawk Industries makes carpet, ceramic tile, laminate and vinyl flooring. It sells in North America and Europe through three units: Global Ceramic, Flooring North America and Flooring Rest of the World. The company is based in Calhoun, Georgia. It reported third-quarter results after the close on Thursday. Revenue came to $2.79 billion, 1.1% below the $2.82 billion consensus. Adjusted earnings were $2.72 a share, 5.4% above the $2.58 expected.
What Drove Mohawk’s Quarter
Its release called it “a solid third quarter in a weak demand environment.”
Global Ceramic sales grew about 2% to $1.13 billion. Flooring North America grew about 1% to $950 million. For the fourth quarter, Mohawk guides to adjusted earnings of $1.35 to $1.45 a share. The midpoint sits 14.6% below the $1.64 consensus. Mohawk pointed to four fewer shipping days and softer flooring demand.
Four Desks Raise Mohawk
Stephen Kim of Evercore ISI upgraded Mohawk to Outperform from In-Line and raised the price target from $129 to $171 today. Timothy Wojs of Baird kept Neutral and raised his target from $132 to $142. Rafe Jadrosich of BofA raised his target from $130 to $147. Later the same day, Matthew Bouley of Barclays kept Equal Weight and raised his target from $115 to $125.
Mohawk’s Record on AnaChart
Mohawk draws 10 covering analysts on AnaChart. Their average target is $123.94. Ratings split 73.53% Hold and 26.47% Buy. AnaChart’s tracking shows 75.29% of Mohawk targets get met, after about 194 days on average. Kim has met 8 of his 10 targets on the stock, with an average potential upside of 3.07%.
What the Performance Matrix Shows
AbbVie has the best met ratio of the three, and Mohawk the lowest. A Mohawk target that gets met lands in about 194 days. Gould and Bansal moved on both drug makers today. AnaChart’s first AbbVie forecast dates to February 2013, and its first Regeneron forecast to July 2010.
AnaChart tracks every price target against what happened to the stock afterward, desk by desk and analyst by analyst. The ticker pages linked above break out each record by analyst, firm and year. AnaChart’s full data set holds more than 760,000 analyst calls on more than 9,000 tickers, active and delisted. More than 680,000 carry a price target and more than 730,000 carry a rating. It is the second largest database of its kind. The raw file is available through the AnaChart store.
The previous update covered Amazon, Intel and Coinbase on October 30.
